On December 9, 2025, Tivic Health Systems acquired the manufacturing and development assets of Scorpius Holdings, launching a new subsidiary, Velocity Bioworks, to provide contract development and manufacturing services. This acquisition allows Tivic to bring manufacturing in-house, reducing costs and accelerating the development of its lead drug, Entolimod, while also creating new revenue opportunities by serving other biotech companies. The acquisition was financed by a $16 million debt and up to $75 million in preferred convertible equity led by 3i, LP. Additionally, Tivic terminated its Equity Purchase Agreement with Mast Hill Fund, L.P. on December 9, 2025.
Tuesday, December 23, 2025
Tivic Health Systems Acquires Scorpius Holdings Assets
On December 9, 2025, Tivic Health Systems acquired the manufacturing and development assets of Scorpius Holdings, launching a new subsidiary, Velocity Bioworks, to provide contract development and manufacturing services. This acquisition allows Tivic to bring manufacturing in-house, reducing costs and accelerating the development of its lead drug, Entolimod, while also creating new revenue opportunities by serving other biotech companies. The acquisition was financed by a $16 million debt and up to $75 million in preferred convertible equity led by 3i, LP. Additionally, Tivic terminated its Equity Purchase Agreement with Mast Hill Fund, L.P. on December 9, 2025.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.